CHINA PHARMA HOLDINGS, INC.(CPHI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 8 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CPHI Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for CHINA PHARMA HOLDINGS, INC. (CPHI), a Healthcare sector company. CPHI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 8 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), CHINA PHARMA HOLDINGS, INC. reports quarterly revenue of $948.3K, net income of $-1.5M. Top institutional holders of CPHI by reported 13-F value include CITADEL ADVISORS, TWO SIGMA SECURITIES, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CPHI trades on the NYSE exchange and files with the SEC under CIK 1106644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPHI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHINA PHARMA HOLDINGS, INC. directly from SEC EDGAR.
Revenue
Q2 2026
$948.3K
Net Income
Q2 2026
$-1.5M
ROIC
Q2 2026
-15.1%
D/E Ratio
Q2 2026
0.05
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-8.5% YoYNet Income
+32.7% YoYOperating Income
+29.4% YoYEPS (Diluted)
+72.7% YoYTotal Assets
+108.2% YoYTotal Debt
+25.3% YoYOp. Cash Flow
+136.5% YoYFree Cash Flow
+120.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.1M -8.5% | $4.5M -35.4% | $7.0M -13.5% | $8.1M -15.9% | $9.6M -11.3% | $10.9M |
| Net Income | $-3.2M +32.7% | $-4.7M -53.8% | $-3.1M +22.5% | $-4.0M -16.9% | $-3.4M -18.6% | $-2.9M |
| Operating Income | $-3.2M +29.4% | $-4.6M -66.8% | $-2.8M +22.5% | $-3.5M -24.1% | $-2.9M -10.9% | $-2.6M |
| EPS (Diluted) | $-0.74 +72.7% | $-2.71 -197.8% | $-0.91 +75.9% | $-3.78 -410.8% | $-0.74 | — |
| Total Assets | $31.0M +108.2% | $14.9M -9.6% | $16.5M -7.4% | $17.8M -21.5% | $22.6M +7.3% | $21.1M |
| Total Debt | $1.4M +25.3% | $1.1M +1.0% | $1.1M | — | — | $5.2M |
| Operating Cash Flow | $148.3K +136.5% | $-406.1K +42.0% | $-699.7K -70.8% | $-409.5K -63.9% | $-249.8K -491.2% | $-42.3K |
| Free Cash Flow | $88.9K +120.0% | $-444.5K +37.5% | $-711.2K +12.4% | $-811.5K -18.0% | $-687.9K +24.4% | $-909.6K |
Get alerted when CPHI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CHINA PHARMA HOLDINGS, INC. including:
Top Institutional Holders of CPHI
CITADEL ADVISORS LLC
$82.8K125,445 shTWO SIGMA SECURITIES, LLC
$23.5K35,666 shRENAISSANCE TECHNOLOGIES LLC
$9.9K15,045 shJANE STREET GROUP, LLC
$9.2K13,886 shGround Swell Capital, LLC
$7.0K10,610 shUBS Group AG
$2.1K3,109 shEFG International AG
$26.0040 shDANSKE BANK A/S
$1.001 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $82.8K | 125,445 |
| TWO SIGMA SECURITIES, LLC | $23.5K | 35,666 |
| RENAISSANCE TECHNOLOGIES LLC | $9.9K | 15,045 |
| JANE STREET GROUP, LLC | $9.2K | 13,886 |
| Ground Swell Capital, LLC | $7.0K | 10,610 |
| UBS Group AG | $2.1K | 3,109 |
| EFG International AG | $26.00 | 40 |
| DANSKE BANK A/S | $1.00 | 1 |
More Healthcare Companies
View all Healthcare →Put CPHI on your watchlist
Track score changes the day CHINA PHARMA HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CPHI a good stock to buy?
13F Pro's AI-powered analysis of CHINA PHARMA HOLDINGS, INC. (CPHI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CPHI are available on the CPHI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CPHI is classified as a small company.
Which hedge funds own CPHI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CPHI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CHINA PHARMA HOLDINGS, INC.'s investment landscape.